Angela N. Johnson

Press Kit

Everything you need

For media inquiries, conference programming, podcast bookings, and interview requests. Bios, headshots, topic areas, and a contact below. Use what you need. No permission required for the materials on this page.

Media contact: angela@angelanjohnson.com


Bios

Short — 50 words

Angela N. Johnson, PhD, RAC is Senior Vice President of Advisory Services at Avania, where she leads the global practice across diligence, regulatory, market access, and engineering leadership for medtech, biotech, and life science. Founder of The Real Cat AI Labs and adjunct faculty at Northeastern University.

Panel — 150 words

Angela N. Johnson, PhD, RAC is Senior Vice President of Advisory Services at Avania, leading the global practice across diligence, regulatory, market access, and engineering leadership for medtech, biotech, and life science. She has led regulatory functions for multiple venture-backed companies through IPOs (Sigilon, Roivant) and strategic exits, with prior roles at GE Healthcare, IQVIA, Roivant, Sigilon, and Cytiva. She is the founder of The Real Cat AI Labs, a 501(c)(3) research nonprofit studying machine cognition, and serves as co-chair of the CMC committee at the American Society of Gene and Cell Therapy. Angela is adjunct faculty in regulatory affairs at Northeastern University and a contributing author to the RAPS regulatory affairs textbooks. She holds a PhD in technical communication from Texas Tech and an MS in materials science from NC State.

Feature — 300 words

Angela N. Johnson, PhD, RAC works in the space where medtech and biotech innovation meets the business of bringing it to market. Diligence frames the bet. Regulatory decides whether the bet is allowed. Market access decides whether anyone gets paid for it. Engineering leadership decides whether the thing actually works. The job is the connective tissue between them.

She is Senior Vice President of Advisory Services at Avania, where she leads the global practice that helps medtech, biotech, and life science companies make the calls that matter. Her clients range from venture-backed startups making their first regulatory bet to multinationals navigating compliance across thirty jurisdictions. Prior to Avania, she held leadership roles at GE Healthcare, IQVIA, Roivant, Sigilon, and Cytiva, and has led the regulatory function for multiple VC-backed companies through IPOs (Sigilon, Roivant) and strategic exits.

Angela is the founder of The Real Cat AI Labs, a 501(c)(3) research nonprofit studying how language models remember, reflect, and refuse. The lab's flagship project, Child1, explores adaptive moral decision-making in AI systems. She is adjunct faculty in regulatory affairs at Northeastern University, contributing author to the RAPS regulatory affairs textbooks, and co-chair of the CMC committee at the American Society of Gene and Cell Therapy. Her 2017 work on synthetic MRI received the Lucien Levy Award for Best Original Research from the American Journal of Neuroradiology.

She holds a PhD in technical communication from Texas Tech University, an MS in materials science and engineering from NC State, and a BFA from East Carolina University. She lives in the Boston area.


Headshots

Click to download full resolution. Approved for editorial use.


Topic areas

What I would love to be asked about. Use these as starting points or as inspiration for sharper questions.

  • Cross-functional executive leadership across medtech and biotech

    Why the most interesting work in life science companies happens in the seams between diligence, regulatory, market access, and engineering. The single-function executive era is ending.

  • Due diligence frameworks for AI-enabled health tech

    What investors and acquirers actually need to evaluate when the product is partly a regulatory bet, partly a clinical bet, and partly an AI bet. A practitioner's view.

  • FDA's PCCP framework and adaptive AI/ML in medical devices

    Why predetermined change control plans are the most important regulatory innovation of the decade, and why most companies are getting them wrong.

  • Market access and reimbursement strategy for novel medtech

    The mistake of treating reimbursement as a launch-year problem. How market access strategy should shape the regulatory plan, not the other way around.

  • The EU AI Act's collision with MDR for digital health

    Two parallel frameworks landing on the same device. What it actually means for product roadmaps in 2026 and 2027.

  • Building cross-functional teams inside venture-backed life science startups

    First executive hire stories. What founders get wrong about the order of operations across reg, clinical, market access, and engineering.

  • Morally-aligned AI and the refusal problem

    An AI that cannot refuse is not aligned, it is just compliant. The Real Cat Labs research thesis.

  • Career paths from technical writing to executive leadership in medtech

    Materials science, technical communication, regulatory affairs, executive advisory. The non-traditional path and the throughline that matters.


Recent press


Affiliations

Contact

For media, speaking, podcast, and interview requests: angela@angelanjohnson.com

Response time is typically 2-3 business days. For time-sensitive inquiries, please indicate the deadline in your subject line.